Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa). Academic Article uri icon

Overview

abstract

  • Bronchorrhea is a condition in which voluminous sputum is produced daily, typically seen with bronchioloalveolar cell carcinoma (BAC). Unless the underlying cancer can be controlled, bronchorrhea causes substantial symptomatic distress. We report two cases of bronchorrhea associated with advanced BAC successfully treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib. Prompt resolution of these patients' bronchorrhea, dyspnea, and supplemental oxygen requirements are detailed. Given the limited success of alternative interventions, a trial of gefitinib should be considered for patients with bronchorrhea secondary to BAC.

publication date

  • November 19, 2004

Research

keywords

  • Adenocarcinoma, Bronchiolo-Alveolar
  • Antineoplastic Agents
  • ErbB Receptors
  • Lung Neoplasms
  • Protein Kinase Inhibitors
  • Quinazolines
  • Sputum

Identity

Scopus Document Identifier

  • 13244291541

PubMed ID

  • 15558327

Additional Document Info

volume

  • 13

issue

  • 1